




RealRate

PHARMACEUTICAL 2023

Tenax Therapeutics INC
Rank 436 of 471



RealRate

The First AI Rating Agency

www.realrate.ai

The relative strengths and weaknesses of Tenax Therapeutics INC are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Tenax Therapeutics INC compared to the market average is the variable Liabilities, increasing the Economic Capital Ratio by 6.9% points. The greatest weakness of Tenax Therapeutics INC is the variable Assets, reducing the Economic Capital Ratio by 79% points.

The company's Economic Capital Ratio, given in the ranking table, is 71%, being 174% points below the market average of 245%.

Input Variable	Value in 1000 USD
Assets, Current	3,208
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	1,848
Liabilities, Non-Current	64
Other Assets	189
Other Compr. Net Income	0
Other Expenses	4.4
Other Liabilities	0
Other Net Income	0
Other Revenues	9.2
Property and Equipment	7.2
Research and Development	5,377
Selling, General and Administrative Expense	5,675

Output Variable	Value in 1000 USD
Assets	3,405
Liabilities	1,912
Expenses	11,057
Revenues	9.2
Stockholders Equity	1,493
Net Income	-11,048
Comprehensive Net Income	-11,048
BaseVar	8,191
ECR before LimitedLiability	-293%
Economic Capital Ratio	71%